Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Capetti · SciRah

Researcher profile · Semantic Scholar

A. Capetti

Share profile

A. Capetti — researcher profile on SciRah

h-index: 25
Works: 122
Citations: 2,286

Most-cited papers

Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12® and Lactobacillus paracasei ssp. paracasei, L. casei 431® in an influenza vaccination model: a randomised, double-blind, placebo-controlled study.
G. Rizzardini, D. Eskesen, P. Calder, A. Capetti +2 more
2012British Journal of Nutrition212 citations Open access
Semantic Scholar
Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders.
S. Piconi, Serena Parisotto, G. Rizzardini, Simone Passerini +7 more
2011Blood182 citations Open access
Semantic Scholar
Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
S. Antinori, C. Bonazzetti, G. Gubertini, A. Capetti +6 more
2020Autoimmunity Reviews150 citations Open access
Semantic Scholar
Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy
S. Piconi, D. Trabattoni, A. Gori, Serena Parisotto +6 more
2010AIDS (London)144 citations Open access
Semantic Scholar
A novel methodology for large-scale phylogeny partition
M. Prosperi, M. Ciccozzi, I. Fanti, F. Saladini +14 more
2011Nature Communications131 citations Open access
Semantic Scholar
Nanoformulation of antiretroviral drugs enhances their penetration across the blood brain barrier in mice.
Luisa Fiandra, M. Colombo, S. Mazzucchelli, M. Truffi +7 more
2015Nanomedicine : nanotechnology, biology, and medicine58 citations Open access
Semantic Scholar
Long term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patients.
G. Baldin, A. Ciccullo, S. Rusconi, A. Capetti +10 more
2019International Journal of Antimicrobial Agents53 citations Open access
Semantic Scholar
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
A. Capetti, M. Cossu, G. Orofino, G. Sterrantino +10 more
2017BMC Infectious Diseases47 citations Open access
Semantic Scholar
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV‐1 replication
A. Borghetti, G. Baldin, F. Lombardi, A. Ciccullo +8 more
2018HIV Medicine43 citations
Semantic Scholar
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.
A. Borghetti, G. Baldin, A. Capetti, G. Sterrantino +11 more
2017AIDS (London)43 citations
Semantic Scholar
Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort
A. Capetti, G. Sterrantino, M. Cossu, G. Orofino +7 more
2016PLoS ONE42 citations Open access
Semantic Scholar
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial
S. Rusconi, P. Vitiello, F. Adorni, E. Colella +25 more
2013PLoS ONE42 citations Open access
Semantic Scholar
Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data
A. Capetti, M. Cossu, G. Sterrantino, G. Barbarini +8 more
2018The Annals of Pharmacotherapy37 citations
Semantic Scholar
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial
M. Fabbiani, R. Gagliardini, N. Ciccarelli, Eugenia Quiros Roldan +167 more
2018Journal of Antimicrobial Chemotherapy34 citations Open access
Semantic Scholar
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: Results from a multicenter cohort study.
B. Rossetti, G. Baldin, G. Sterrantino, S. Rusconi +12 more
2019Antiviral Research32 citations Open access
Semantic Scholar
A Comparison between two Dolutegravir-Based two-drug Regimens as Switch Strategies in a Multicentre Cohort of HIV-1-Infected Patients
A. Ciccullo, G. Baldin, A. Capetti, S. Rusconi +10 more
2018Antiviral Therapy31 citations Open access
Semantic Scholar
Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding
A. Ciccullo, V. Borghi, A. Giacomelli, M. Cossu +12 more
2021Journal of Acquired Immune Deficiency Syndromes28 citations Open access
Semantic Scholar
Efficacy and durability of two‐ vs. three‐drug integrase inhibitor‐based regimens in virologically suppressed HIV‐infected patients: Data from real‐life ODOACRE cohort
M. Fabbiani, B. Rossetti, A. Ciccullo, L. Oreni +13 more
2021HIV Medicine28 citations
Semantic Scholar
Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems
S. Melzi, L. Carenzi, M. Cossu, Simone Passerini +2 more
2010Cholesterol27 citations Open access
Semantic Scholar
Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance
A. Capetti, M. Cossu, G. Rizzardini
2015Expert Opinion on Pharmacotherapy26 citations
Semantic Scholar
Salvage Therapy or Simplification of Salvage Regimens with Dolutegravir plus Ritonavir-Boosted Darunavir Dual Therapy in Highly cART-Experienced Subjects: An Italian Cohort
A. Capetti, G. Sterrantino, M. Cossu, G. Cenderello +9 more
2016Antiviral Therapy25 citations
Semantic Scholar
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV‐infected patients in clinical practice: results from a multicentre, observational study
G. Baldin, A. Ciccullo, A. Capetti, S. Rusconi +9 more
2018HIV Medicine20 citations
Semantic Scholar
Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art
Luisa Fiandra, A. Capetti, L. Sorrentino, F. Corsi
2017Journal of Neuroimmune Pharmacology19 citations Open access
Semantic Scholar
Transmitted HIV Type 1 Drug Resistance and Non-B Subtypes Prevalence among Seroconverters and Newly Diagnosed Patients from 1992 to 2005 in Italy
C. Riva, A. Lai, I. Caramma, S. Corvasce +14 more
2010AIDS Research and Human Retroviruses19 citations
Semantic Scholar
Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection?
A. Capetti, S. Piconi, S. Landonio, G. Rizzardini +1 more
2009Journal of Acquired Immune Deficiency Syndromes19 citations Open access
Semantic Scholar
The prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients.
R. Ungaro, L. Taramasso, B. Bruzzone, I. Vicenti +103 more
2019Clinical Microbiology and Infection18 citations Open access
Semantic Scholar
Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects
A. Capetti, G. D. De Socio, M. Cossu, G. Sterrantino +10 more
2018HIV Clinical Trials18 citations Open access
Semantic Scholar
Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference
C. Gervasoni, A. Riva, Valeria Cozzi, A. Capetti +3 more
2017Journal of Antimicrobial Chemotherapy18 citations Open access
Semantic Scholar
Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.
A. Capetti, P. Meraviglia, S. Landonio, G. Sterrantino +17 more
2014International Journal of Antimicrobial Agents18 citations Open access
Semantic Scholar
Brief Report: Impact of the COVID-19 Pandemic on Virological Suppression in People Living With HIV Attending a Large Italian HIV Clinic
A. Giacomelli, C. Bonazzetti, F. Conti, L. Pezzati +13 more
2021Journal of Acquired Immune Deficiency Syndromes17 citations Open access
Semantic Scholar
Drug–drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment
D. Cattaneo, A. Capetti, G. Rizzardini
2019Expert Opinion on Drug Metabolism & Toxicology17 citations
Semantic Scholar
96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience
A. Capetti, S. Landonio, P. Meraviglia, A. di Biagio +17 more
2012PLoS ONE17 citations Open access
Semantic Scholar
The future of long-acting cabotegravir plus rilpivirine therapy: Deeds and misconceptions.
S. Rusconi, M. Santoro, A. Capetti, N. Gianotti +1 more
2022International Journal of Antimicrobial Agents15 citations Open access
Semantic Scholar
Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort
A. Ciccullo, G. Baldin, V. Borghi, G. Sterrantino +11 more
2020AIDS Research and Human Retroviruses15 citations Open access
Semantic Scholar
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
A. di Biagio, R. Prinapori, D. Giannarelli, F. Maggiolo +10 more
2013Journal of Antimicrobial Chemotherapy14 citations Open access
Semantic Scholar
Impressive boosting of anti-S1/S2 IgG production in COVID-19-experienced patients after the first shot of the BNT162b2 mRNA COVID-19 Vaccine
A. Capetti, C. A. Stangalini, Fábio Borgonovo, D. Mileto +8 more
2021Clinical Infectious Diseases13 citations Open access
Semantic Scholar
Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection
A. Capetti, M. Cossu, L. Paladini, G. Rizzardini
2018Expert Opinion on Pharmacotherapy13 citations
Semantic Scholar
Transmission of Resistant HIV Type 1 Variants and Epidemiological Chains in Italian Newly Diagnosed Individuals
A. Lai, M. Violin, Erika Ebranati, M. Franzetti +10 more
2012AIDS Research and Human Retroviruses13 citations Open access
Semantic Scholar
Choosing appropriate pharmacotherapy for drug-resistant HIV
A. Capetti, G. Rizzardini
2019Expert Opinion on Pharmacotherapy12 citations
Semantic Scholar
Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers
E. Clementi, M. Cossu, D. Cattaneo, Serena Fucile +4 more
2014Drug Design, Development and Therapy12 citations Open access
Semantic Scholar
Concomitant diagnosis of sexually transmitted infections and human monkeypox in patients attending a sexual health clinic in Milan, Italy
A. Rizzo, G. Pozza, F. Salari, A. Giacomelli +11 more
2022Journal of Medical Virology11 citations
Semantic Scholar
Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort
A. Ciccullo, G. Baldin, V. Borghi, F. Lagi +12 more
2022Viruses11 citations Open access
Semantic Scholar
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study.
G. Baldin, A. Ciccullo, S. Rusconi, G. Madeddu +11 more
2019Le infezioni in medicina11 citations
Semantic Scholar
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
A. Ciccullo, G. Baldin, A. Capetti, V. Borghi +18 more
2019BMJ Open11 citations Open access
Semantic Scholar
Shall We Dance? Extending TANGO’s Results to Clinical Practice
A. Borghetti, A. Ciccullo, G. Baldin, S. Rusconi +6 more
2020Clinical Infectious Diseases10 citations Open access
Semantic Scholar
Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.
A. di Biagio, N. Riccardi, L. Taramasso, A. Capetti +8 more
2016International Journal of Antimicrobial Agents10 citations
Semantic Scholar
Antiretroviral Therapy through Barriers: A Prominent Role for Nanotechnology in HIV-1 Eradication from Sanctuaries
F. Corsi, L. Sorrentino, S. Mazzucchelli, M. Truffi +3 more
201610 citations Open access
Semantic Scholar
Cobicistat: a new opportunity in the treatment of HIV disease?
A. Capetti, G. Rizzardini
2014Expert Opinion on Pharmacotherapy10 citations
Semantic Scholar
Four years of immunization with OM-85 BV to prevent respiratory infections in HIV+ patients
A. Capetti, M. Cossu, L. Carenzi, G. Rizzardini
2013Human Vaccines & Immunotherapeutics10 citations Open access
Semantic Scholar
Late HIV seroconversion after non-occupational postexposure prophylaxis against HIV with concomitant hepatitis C virus seroconversion.
R. Terzi, F. Niero, E. Iemoli, A. Capetti +2 more
2007AIDS (London)10 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Rizzardini×25
Invite
G. Rizzardini — researcher profile on SciRah
S. Rusconi×21
Invite
S. Rusconi — researcher profile on SciRah
G. Sterrantino×21
Invite
G. Sterrantino — researcher profile on SciRah
M. Cossu×21
Invite
M. Cossu — researcher profile on SciRah

S. Di Giambenedetto

×20

Invite

S. Di Giambenedetto — researcher profile on SciRah

Invite

G. Baldin — researcher profile on SciRah

A. Ciccullo×12

Invite

A. Ciccullo — researcher profile on SciRah

G. d'Ettorre×10

Invite

G. d'Ettorre — researcher profile on SciRah

A. di Biagio×10

Invite

A. di Biagio — researcher profile on SciRah

P. Meraviglia×9

Invite

P. Meraviglia — researcher profile on SciRah

Invite

V. Borghi — researcher profile on SciRah

Invite

A. De Luca — researcher profile on SciRah